Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 314

1.

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.

Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C.

BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z.

2.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group..

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
3.

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group..

AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. No abstract available.

PMID:
28079545
4.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.

Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S.

J Chemother. 2016 Dec 26:1-9. doi: 10.1080/1120009X.2016.1269040. [Epub ahead of print]

PMID:
28019192
5.

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.

Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, De Luca A, Gianotti N.

J Infect. 2016 Dec;73(6):619-623. doi: 10.1016/j.jinf.2016.08.011. Epub 2016 Aug 26. No abstract available.

PMID:
27575581
6.

Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.

Lombardi F, Belmonti S, Fabbiani M, Borghetti A, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Dec;71(12):3621-3622. Epub 2016 Aug 3. No abstract available.

PMID:
27494930
7.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).

Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S.

Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1457-1468. Epub 2016 May 16.

PMID:
27180611
8.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4. No abstract available.

PMID:
27147306
9.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

PMID:
25885326
10.

Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.

Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):433-40. doi: 10.3851/IMP2925. Epub 2014 Dec 11.

PMID:
25504667
11.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.

Borghetti A, Mondi A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19817. doi: 10.7448/IAS.17.4.19817. eCollection 2014.

12.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

13.

Liver fibrosis is associated with cognitive impairment in HIV-positive patients.

Ciccarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondi A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19722. doi: 10.7448/IAS.17.4.19722. eCollection 2014.

14.

Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk.

D'Avino A, Lassandro A, Lamonica S, Piccoli B, Fabbiani M, Mondi A, Gagliardini R, Borghetti A, Fanti I, Pallavicini F, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19570. doi: 10.7448/IAS.17.4.19570. eCollection 2014.

15.

Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals.

Borghetti A, Cattani P, Maria G, D'Onghia S, Santangelo R, Marchetti S, Farina S, Cauda R, De Luca A, Di Giambenedetto S.

J Infect. 2015 Jan;70(1):60-71. doi: 10.1016/j.jinf.2014.07.025. Epub 2014 Aug 15.

PMID:
25135229
16.

Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure.

Fabbiani M, Grima P, Borghetti A, Colafigli M, D'Avino A, Mondi A, Gagliardini R, De Luca A, Cauda R, Di Giambenedetto S.

J Infect. 2014 May;68(5):500-3. doi: 10.1016/j.jinf.2014.01.012. Epub 2014 Feb 6. No abstract available.

PMID:
24509141
17.

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.

Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D'Avino A, Mondi A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S.

BMC Infect Dis. 2014 Jan 13;14:26. doi: 10.1186/1471-2334-14-26.

18.

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.

Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

BMC Infect Dis. 2012 Nov 12;12:296. doi: 10.1186/1471-2334-12-296.

19.

Peri-implantitis: from diagnosis to therapeutics.

Nguyen-Hieu T, Borghetti A, Aboudharam G.

J Investig Clin Dent. 2012 May;3(2):79-94. doi: 10.1111/j.2041-1626.2012.00116.x. Epub 2012 Mar 1. Review.

PMID:
22383175
20.

The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.

Romani AA, Desenzani S, Morganti MM, Baroni MC, Borghetti AF, Soliani P.

Cancer Chemother Pharmacol. 2011 Mar;67(3):557-67. doi: 10.1007/s00280-010-1345-6. Epub 2010 May 15.

PMID:
20473610

Supplemental Content

Loading ...
Support Center